# A Composite Assay for HER2-positive Early-stage Breast Cancer Management

> **NCT06762977** · — · RECRUITING · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 180 (estimated)

## Conditions studied

- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- HER2

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06762977
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-13
- **Primary completion:** 2025-08
- **Final completion:** 2026-08
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2025-01-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06762977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06762977, "A Composite Assay for HER2-positive Early-stage Breast Cancer Management". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06762977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*